Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology

Upcoming Clinical Trials for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Emerging Therapies in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Antibody Drug Conjugates for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Neoadjuvant Therapy Versus Surgery for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

New Data for Secondary Surgery in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

PARP Inhibitors in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Expert Approaches for Treating Recurrent Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Emerging Combinations in the Frontline Setting of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Patient Preference for Treatment in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

PAOLA-1 Study Surgical Subset for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Personalized Dosing of Niraparib in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Treating Homologous Recombination Proficient Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Treating BRCA+ Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Need for Frontline Comparison Trials in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Impact of HRD Status on Frontline Treatment of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Biomarker-Driven Frontline Ovarian Cancer Treatment

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

An Introduction to the Discussion of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Dr. Monk on the FDA Approval of Maintenance Rucaparib in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology

April 6th 2018

Bradley J. Monk, MD, FACOG, FACS, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Arizona Oncology, discusses the FDA approval of rucaparib (Rubraca) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Dr. Monk Discusses Immunotherapy in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology

December 12th 2017

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for the treatment of patients with ovarian cancer.

How Reliable Is PD-L1 Expression as a Predictor of Immune Response?

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology

November 9th 2017

There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.

Dr. Monk on Immunotherapy for Gynecologic Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology

April 18th 2017

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for patients with gynecologic cancer.